• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    FOXO Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

    8/18/25 5:19:55 PM ET
    $FOXO
    Life Insurance
    Finance
    Get the next $FOXO alert in real time by email
    false 0001812360 0001812360 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    Date of Report (Date Earliest Event Reported): August 12, 2025

     

    FOXO TECHNOLOGIES INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39783   85-1050265
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    477 South Rosemary Avenue
    Suite 224
    West Palm Beach, Florida

      33401
    (Address of Principal Executive Offices)   (Zip Code)

     

    (612) 800-0059

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A Common Stock, par value $0.0001   FOXO   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On August 12, 2025, FOXO Technologies Inc., a Delaware corporation (the “Company”), received a letter from NYSE confirming that NYSE Regulation has determined to commence proceedings to delist the Class A Common Stock of the Company from NYSE American, pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Class A Common Stock. The share price went below the NYSE minimum price of $0.10 on August 12, 2025 and was immediately suspended from trading by NYSE.

     

    The Company submitted an application to have its common stock traded on the OTC and has on August 12, 2025 received confirmation from FINRA’s Department of Market Operations that the trading symbol, “FOXO” has been assigned by them to the Common Stock of FOXO Technologies, Inc., and that the Company’s Class A Common Stock commenced trading on the OTC market as of August 13, 2025.

     

    Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

     

    On August 14, 2025, the board of directors (the “Board”) of the Company concluded that the previously issued unaudited condensed consolidated financial statements contained in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “Original 10-Q”) should no longer be relied upon because of an error in those financial statements relating to the Company’s accounting for measurement-period purchase price consideration owed in connection with the Company’s acquisition on September 10, 2024 of Rennova Community Health, Inc. (“RCHI”) from Rennova Health, Inc. (“RHI”). In connection with the preparation of the Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2025, the Company determined that certain measurement-period purchase price consideration that had been settled as of March 31, 2025, should have been recorded in its financial statements at March 31, 2025 under the terms of the purchase agreement as follows:

     

    On June 10, 2024, the Company entered into a stock exchange agreement dated June 10, 2024, (the “RCHI Agreement”), as amended and restated on September 10, 2024 (the “RCHI SEA”), which provided for RHI to exchange all of the outstanding shares of its subsidiary RCHI, including RCHI’s subsidiary Scott County Community Hospital, Inc. (“SCCH”), for a combination of equity and debt of the Company.

     

    Per the terms of the RCHI SEA, in the event that the Company at any time after June 10, 2024 and during the twelve months thereafter, entered into any agreement or settlement agreement with any pre-existing holder of debt or other liability owed by the Company above $5.0 million (cumulative) then the consideration payable to RHI shall increase on a dollar-for-dollar basis for the aggregate settlement amount above $5.0 million. As of the September 10, 2024 acquisition date, the full scope of the Company’s obligations to pre-existing debt holders or other creditors was not determinable, as negotiations with creditors and debt holders remained open and unresolved. As of March 31, 2025, the Company had fully settled $5.1 million of cumulative debts and liabilities above $5.0 million, and, therefore, the Company should have recorded the additional purchase price consideration of $5.1 million for those completed settlements as a liability in its financial statements at March 31, 2025.

     

    Accounting Standards Codification 805-10-25-13 through 25-20, states a business combination allows for a measurement period of up to one year following the acquisition date to adjust provisional amounts based on new information about facts and circumstances that existed as of the acquisition date. The obligation to increase the purchase price consideration based on settlements with pre-acquisition debt holders and creditors represents a contingent liability that:

     

    1.Existed as of the acquisition date- as the debts were pre-existing and known in general terms.
       
    2.The total liability payable could not be reasonably estimated at the time of acquisition due to ongoing negotiations, an expectation that the numbers payable would change and lack of final payment or settlement. In fact, the liability only materialized at the time of settlement/payment as has been demonstrated by several adjustments at that point for some of the qualifying liabilities.
       
    3.It was based on a terms outlined in the acquisition agreement, which anticipated measurement at one-year post-acquisition. It was expected that all matters could be resolved and finalized in one year, but that time frame has proved ambitious with a number of identified items remaining open past the one-year timeframe.
       
    4.Was resolved within the measurement period via settlement agreements that reflected facts and circumstances that existed as of the acquisition date but often reflected an adjustment (to the advantage of the Company) from the liability in our records.

     

    Based on the accounting guidance noted above, the Company intends to amend its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 to record the portion of the provisional purchase price obligation that was settled as of March 31, 2025. The settlement amount of $5.1 million will be recorded at March 31, 2025 as an increase in goodwill and a payable to RHI for the purchase of RCHI.

     

     

     

     

    The correction of the error impacted the unaudited condensed consolidated balance sheet, the acquisition footnote, the related parties’ payables and accrued expenses footnote, the supplemental disclosure of cash flow information and the disclosure of working capital deficit in the footnotes and in Management Discussion and Analysis at March 31, 2025. The correction of the error did not impact the statement of operations, stockholders’ equity, total cash flows, net loss or comprehensive loss.

     

    The effect of the restatement on the Company’s unaudited condensed consolidated balance sheet as of March 31, 2025 is as follows:

     

    Unaudited Condensed Consolidated Balance Sheets Data

     

       As
    Previously
    Reported
    March 31, 2025
       Correction   As
    Restated
    March 31, 2025
     
                 
    Assets               
    Total current assets  $3,194,691   $-   $3,194,691 
    Goodwill   25,463,948    5,132,928    30,596,876 
    Other long terms assets   13,219,813         13,219,813 
    Total assets  $41,878,452   $5,132,928   $47,011,380 
                    
    Liabilities and Stockholders’ Equity               
    Current liabilities               
    Related parties’ payables and accrued expenses  $1,841,883    5,132,928   $6,974,811 
    Other current liabilities   26,815,782    -    26,815,782 
    Total current liabilities   28,657,665    5,132,928    33,790,593 
    Noncurrent liabilities   3,567,941    -    3,567,941 
    Total liabilities   32,225,606    5,132,928    37,358,534 
    Commitments and contingencies               
    Stockholders’ equity               
    Total stockholders’ equity   9,652,846    -    9,652,846 
    Total liabilities and stockholders’ equity  $41,878,452   $5,132,928   $47,011,380 

     

    The Effect on the Acquisition Footnote is as Follows:

     

    Acquisition of RCHI

     

      

    As

    Previously

    Reported at

    March 31, 2025

       Correction  

    As
    Restated at

    March 31, 2025

     
    Initial purchase price  $22,000,100   $-   $22,000,100 
    Additional purchase price consideration   -    5,132,928    5,132,928 
    Total purchase price  $22,000,100   $5,132,928   $27,133,028 
    Tangible and intangible assets acquired, net of liabilities assumed at fair value:               
    Tangible and intangible assets acquired  $14,274,919   $-   $14,274,919 
    Liabilities assumed   (15,864,997)   -    (15,864,997)
    Assets acquired, net of liabilities assumed   (1,590,078)   -    (1,590,078)
    Goodwill  $23,590,178   $5,132,928   $28,723,106 

     

     

     

     

    The Effect on the Related Parties’ Payables and Accrued Expenses Footnote is as Follows:

     

      

    As
    Previously
    Reported at
    March 31, 2025

       Correction  

    As
    Restated at

    March 31, 2025

     
    Payable to RHI for purchase of RCHI  $-   $5,132,928   $5,132,928 
    Total other related parties’ payable and accrued expenses   1,841,883    -    1,841,883 
    Total related parties’ payables and accrued expenses  $1,841,883   $5,132,928   $6,974,811 

     

    Correction of Supplement Cash Flow Information:

     

      

    As
    Previously
    Reported

    March 31, 2025

       Correction  

    As
    Restated

    March 31, 2025

     
                 
    Purchase of RCHI  $             -   $5,132,928   $5,132,928 
    Payable to RHI for purchase of RCHI  $-   $5,132,928   $5,132,928 

     

    Revision to Working Capital Deficit Disclosure:

     

    Working capital deficit  $(25,462,974)  $(5,132,928)  $(30,595,902)

     

    In addition, due to a scrivener’s error, the notes payable and the notes payable related parties amounts were inadvertently switched on the unaudited condensed consolidated balance sheet in the Original 10-Q for the three months ended March 31, 2025. The amount reflected on the notes payable line item of $2,945,950 should have been $2,587,513 and the amount reflected on the notes payable related party line item of $2,587,513 should have been $2,945,950. This error will be corrected on the amended March 31, 2025 unaudited condensed consolidated balance sheet.

     

    The Company plans to file an amended Quarterly Report on Form 10-Q for the three months ended March 31, 2025 to include the unaudited condensed consolidated financial statements for the three months ended March 31, 2025 and related disclosures reflecting the correction of the errors described above and their related effects as soon as practicable.

     

    The Board and the Company’s management have discussed the matters in this Current Report on Form 8-K with its independent registered public accounting firm, Kreit & Chiu CPA LLP.

     

    Cautionary Note Regarding Forward-Looking Statements

     

    Information contained in this Current Report on Form 8-K, other than historical information, may be considered “forward-looking statements.” Forward-looking statements involve known and unknown risks, assumptions, uncertainties, and other factors. Statements made in the future tense, and statements using words such as “anticipates,” “will,” “plans,” “may,” “can,” “could,” “should,” “believe,” “think” or similar expressions are intended to identify forward-looking statements, including statements about the Company’s expectations in regard to the impact the errors described above will have on its unaudited condensed consolidated financial statements for the three months ended March 31, 2025 and the anticipated filing of the Amended 10-Q. Forward-looking statements are not a guarantee of performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and are beyond the Company’s control, and which risks and uncertainties have been described in greater detail in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. Factors that could cause or contribute to such differences include: the review of the Company’s accounting, accounting policies and internal control over financial reporting; the preparation of the review, as applicable, of the Original 10-Q, the Amended 10-Q and the Company’s other filings with the Securities and Exchange Commission; and the subsequent discovery of additional adjustments to the Company’s previously issued financial statements. Actual events or results may differ materially from the Company’s expectations. In addition, the Company’s financial results and stock price may suffer as a result of this review and any subsequent determinations from this process or any actions taken by governmental or other regulatory bodies as a result of this process. The Company cautions you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Report or an earlier date as may be indicated. The Company disclaims any obligation to update any of these forward-looking statements as a result of new information, future events, or otherwise, except as expressly required by law.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      FOXO Technologies Inc.
         
    Dated: August 18, 2025 By: /s/ Seamus Lagan
        Seamus Lagan
      Title: Chief Executive Officer and Interim Chief Financial Officer

     

     

     

    Get the next $FOXO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOXO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FOXO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FOXO TECHNOLOGIES INC. ANNOUNCES THAT ITS COMMON STOCK CAN BE QUOTED AND TRADED ON THE OVER THE COUNTER MARKET FROM AUGUST 13, 2025.

    WEST PALM BEACH, FLORIDA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. ("FOXO" or the "Company") announces that it has received a letter from NYSE on August 12, 2025 confirming that NYSE Regulation has determined to commence proceedings to delist the Class A common stock of FOXO (Ticker symbol FOXO) from NYSE American, pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Class A commons stock. The share price went below the NYSE minimum price of $0.10 on August 12, 2025 and was immediately suspended from trading by NYSE. The Company submitted an application to have its common stock traded on the OTC and has on August 12, 2025 re

    8/13/25 7:52:00 AM ET
    $FOXO
    Life Insurance
    Finance

    FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR AN ASSISTED-LIVING FACILITY IN SOUTH FLORIDA FOR A TOTAL CONSIDERATION OF $22 MILLION

    WEST PALM BEACH, FLORIDA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company") announces that it has executed a non-binding acquisition agreement to acquire an assisted living and memory care facility in South Florida. The proposed acquisition includes the land and buildings. The facility has 87 units licensed for the provision of assisted living and memory care services. The purchase price for the facility is expected to be $22 million, a portion of which is milestone-based. $5M of the purchase price will be in the form of non-convertible preferred stock. Completion of the acquisition is subject to definitive agreements and a number of closing co

    8/6/25 7:43:00 AM ET
    $FOXO
    Life Insurance
    Finance

    FOXO TECHNOLOGIES INC.'S BIG SOUTH FORK MEDICAL CENTER COMPLETES PERFORMANCE NETWORK AGREEMENT WITH COVENANT HEALTH TO PROVIDE SWING BED SERVICES

    WEST PALM BEACH, FLORIDA, Aug. 01, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company") today announced that its critical access designated rural hospital, Big South Fork Medical Center located in Oneida, Tennessee, has completed a Performance Network Agreement with Covenant Health to join their performance network as a provider of swing bed services. Covenant Health is a large, muti-facility hospital network serving greater Knoxville and East Tennessee. Patients who no longer meet acute care admission criteria are frequently in need of post-acute care to enhance their recovery. Big South Fork Medical Center is well positioned to provide swing bed services

    8/1/25 7:52:00 AM ET
    $FOXO
    Life Insurance
    Finance

    $FOXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by FOXO Technologies Inc.

    SC 13G/A - FOXO TECHNOLOGIES INC. (0001812360) (Subject)

    11/7/24 8:46:01 AM ET
    $FOXO
    Life Insurance
    Finance

    Amendment: SEC Form SC 13D/A filed by FOXO Technologies Inc.

    SC 13D/A - FOXO TECHNOLOGIES INC. (0001812360) (Subject)

    9/23/24 4:15:07 PM ET
    $FOXO
    Life Insurance
    Finance

    SEC Form SC 13D filed by FOXO Technologies Inc.

    SC 13D - FOXO TECHNOLOGIES INC. (0001812360) (Subject)

    8/5/24 4:15:29 PM ET
    $FOXO
    Life Insurance
    Finance

    $FOXO
    SEC Filings

    View All

    SEC Form 25-NSE filed by FOXO Technologies Inc.

    25-NSE - FOXO TECHNOLOGIES INC. (0001812360) (Subject)

    8/22/25 11:27:59 AM ET
    $FOXO
    Life Insurance
    Finance

    SEC Form 10-Q filed by FOXO Technologies Inc.

    10-Q - FOXO TECHNOLOGIES INC. (0001812360) (Filer)

    8/19/25 4:01:13 PM ET
    $FOXO
    Life Insurance
    Finance

    Amendment: SEC Form 10-Q/A filed by FOXO Technologies Inc.

    10-Q/A - FOXO TECHNOLOGIES INC. (0001812360) (Filer)

    8/19/25 10:52:54 AM ET
    $FOXO
    Life Insurance
    Finance

    $FOXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Langley Trevor claimed ownership of 1,023,629 shares (SEC Form 3)

    3 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)

    9/12/24 5:28:21 PM ET
    $FOXO
    Life Insurance
    Finance

    New insider Lagan Seamus claimed ownership of 1,023,629 shares (SEC Form 3)

    3 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)

    9/12/24 5:27:29 PM ET
    $FOXO
    Life Insurance
    Finance

    Large owner Kr8 Ai Inc. sold $325,000 worth of shares (1,300,000 units at $0.25), closing all direct ownership in the company (SEC Form 4)

    4 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)

    7/24/24 4:00:23 PM ET
    $FOXO
    Life Insurance
    Finance

    $FOXO
    Leadership Updates

    Live Leadership Updates

    View All

    FOXO TECHNOLOGIES INC.'S BIG SOUTH FORK MEDICAL CENTER COMPLETES PERFORMANCE NETWORK AGREEMENT WITH COVENANT HEALTH TO PROVIDE SWING BED SERVICES

    WEST PALM BEACH, FLORIDA, Aug. 01, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company") today announced that its critical access designated rural hospital, Big South Fork Medical Center located in Oneida, Tennessee, has completed a Performance Network Agreement with Covenant Health to join their performance network as a provider of swing bed services. Covenant Health is a large, muti-facility hospital network serving greater Knoxville and East Tennessee. Patients who no longer meet acute care admission criteria are frequently in need of post-acute care to enhance their recovery. Big South Fork Medical Center is well positioned to provide swing bed services

    8/1/25 7:52:00 AM ET
    $FOXO
    Life Insurance
    Finance

    FOXO TECHNOLOGIES INC. CREATES ACQUISITION VEHICLE AND APPOINTS NEW INTERIM CFO

    WEST PALM BEACH, FLORIDA, June 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company") today announced that it formed a new, wholly-owned subsidiary intended to be used to acquire identified acquisition targets in the healthcare services and related sectors. On June 13, 2025, the Company formed FOXO Acquisition Corporation, a Florida corporation, for the purpose of acquiring targeted acquisitions. The Company also intends to create a new series of non-convertible preferred stock with a goal to have this preferred stock publicly listed (with its own trading symbol) and use it to as a mechanism to complete such acquisitions. The new series of preferred stoc

    6/16/25 7:43:00 AM ET
    $FOXO
    Life Insurance
    Finance

    FOXO TECHNOLOGIES INC. ANNOUNCES RESTRUCTURING AND CAPITAL RAISING TRANSACTIONS AND APPOINTS SEAMUS LAGAN AS CHIEF EXECUTIVE OFFICER

    MINNEAPOLIS, MN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO") announces a series of restructuring and capital raising transactions which will improve the Company's balance sheet, satisfy minimum stockholders' equity requirements of the NYSE American and provide capital for growth and reduce outstanding liabilities. The Company also announces a change in senior leadership. Key transactions include: Rennova Health, Inc.'s exchange of approximately $21 million of a Senior Secured Note issued by Rennova Community Health, Inc., the Company's subsidiary, into 21,000 shares of the Company's Series A Cumulative Convertible Redeemable Pr

    12/11/24 8:00:00 AM ET
    $FOXO
    Life Insurance
    Finance

    $FOXO
    Financials

    Live finance-specific insights

    View All

    FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS

    WEST PALM BEACH, FLORIDA, June 27, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company") today announced that it has designated a new series of its preferred stock (Series E Cumulative Redeemable Secured Preferred Stock e (the "Series E Preferred Stock")) and filed the series' certificate of designation with the Secretary of State of Delaware. The newly designated series of preferred stock includes: (i) a stated value of $25.00 per share, (ii) a 2.5% per annum cash dividend paid semi-annually, (iii) a 5.0% per annum common stock dividend paid semi-annually, and (iv) a security interest in the stock of the Company's recently formed acquisition vehicle, FOXO A

    6/27/25 7:27:00 AM ET
    $FOXO
    Life Insurance
    Finance

    FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY

    MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO on what has been achieved in recent months and what is planned for 2025 and beyond. Dear Fellow Shareholders, Our recent shareholders meeting on January 17th concluded the requirements of 2024 acquisition agreements and resulted in a change of control of the Company. The accomplishments in the second half of 2024 have been key to what we believe is becoming a very successful turnaround of our Company and has created a foundation from which we believe we can build a significant and profitable

    1/28/25 8:05:00 AM ET
    $FOXO
    Life Insurance
    Finance

    FOXO TECHNOLOGIES INC., PROVIDES UPDATE ON 2024 ACCOMPLISHMENTS AND PLANS FOR REMAINDER OF THE YEAR

    MINNEAPOLIS, MN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO"), provides a shareholder letter from Mark White, Interim CEO of FOXO, on what has been achieved in 2024 and what is planned for the remainder of 2024 and beyond. Dear Fellow Shareholders, 2024 has been an exciting, tumultuous and productive year for us. We believe the accomplishments already completed and that we believe will be achieved before year-end create a foundation from which we can build a successful enterprise that will increase shareholder value. The Company began 2024 with a continued focus on commercializing its epigenetic technology while, at the same ti

    10/15/24 8:30:00 AM ET
    $FOXO
    Life Insurance
    Finance